# Oncimmune Holdings paper highlights potential of ImmunoINSIGHTS in the early diagnosis of Rheumatoid arthritis

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-paper-highlights-potential-of-immunoinsights-in-the-early-diagnosis-of-rheumatoid-arthritis/412840319
- Published: 2020-07-08T07:13:41+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), the leading global immunodiagnostics group,
has noted the publication of research, supported by its ImmunoINSIGHTS team, in 
_Arthritis Research & Therapy_^(1), entitled _‘Profiling IgG antibodies targeting
unmodified and corresponding citrullinated autoantigens in a multicentre national
cohort of early arthritis in Germany’_. The published paper demonstrates the potential
to improve early Rheumatoid arthritis (RA) detection using autoantibodies, which,
when combined with appropriate therapy/treatment could substantially improve outcomes
for patients.

ImmunoINSIGHTS, Oncimmune’s autoantibody profiling technology and service business,
continues to work in partnership with therapy developers to generate, actionable,
value-adding insights for their drug development programmes.

Rheumatoid arthritis is characterised by an inflammation with subsequent progressive
destruction of joints. Approximately one-third of people stop work because of RA
within 2 years of its onset, increasing thereafter. However, the currently widely
available tests for rheumatoid factor and anti-citrullinated peptide antibodies (
ACPA) can only be detected in 70-80% of RA patients, and hence the disease is commonly
under-diagnosed.

The aim of the research, led by Oncimmune’s Dr. Petra Buddle and Dr Hans-Dieter 
Zucht, was to assess the diagnostic potential of IgG antibodies to citrullinated
and corresponding native autoantigens in early arthritis. The multicentre study 
involved a total of 411 patients, enrolled at baseline, and a serum sample drawn
for autoantibody profiling. 309 (75.2%) patients were eventually classified as having
RA. For further analysis, the cohort was randomly split into a test cohort (n = 
329) and a validation cohort (n = 82). Patients eventually classified as having 
RA during follow-up were compared to patients who were not classified as having 
RA during follow-up.

The paper concludes that the autoantibody, cTRA2B-IgG, has the potential to improve
diagnosis of early stage rheumatoid arthritis, which to date has been challenging
due to current availability of diagnostics in the therapeutic area.

> **Dr Adam M Hill, CEO of Oncimmune Holdings said:**_ “Oncimmune’s ImmunoINSIGHTS
> team have once again contributed world class science to our collective understanding
> of a disabling disease, moving the needle in a hard to treat condition. RA is 
> insidious in onset, often resulting in a diagnosis later in the evolution of the
> disease; clearly, candidate biomarkers able to identify the disease earlier in
> the majority of sufferers presents a near term opportunity to dramatically improve
> outcomes. Whilst we remain steadfast in our commitment to cancer patients – supporting
> the clinical understanding of autoimmune disease biomarkers better enables us 
> to predict side effects in cancer patients treated with immune modulating drugs–
> the potential to work with biopharma in autoimmune disease is also a possibility”._

Share on:
